Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

BACKGROUND. The current method for assessing progressive disease (PD) in glioblastoma is according to the Response Assessment in Neuro-Oncology (RANO) criteria. Bevacizumab-treated patients may show pseudo-response on postcontrast T1-weighted (T1w) MRI, and a more infiltrative non-enhancing growth p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Gahrmann, Renske, van den Bent, Martin, van der Holt, Bronno, Vernhout, René Michel, Taal, Walter, Vos, Maaike, de Groot, Jan Cees, Beerepoot, Laurens Victor, Buter, Jan, Flach, Zwenneke Hendrieke, Hanse, Monique, Jasperse, Bas, Smits, Marion
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464446/
https://ncbi.nlm.nih.gov/pubmed/28204639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now311
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller